Inventor
SCHARENBERG ANDREW M
US24 patents
⚠️ This page may combine multiple inventors who share the name “SCHARENBERG ANDREW M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SEATTLE CHILDRENS HOSPITAL
16 patentsUS9943612B2Apr 17, 2018
Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid
SEATTLE CHILDRENS HOSPITAL12 citations79
US11753460B2Sep 12, 2023
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
SEATTLE CHILDRENS HOSPITAL2 citations72
US11713459B2Aug 1, 2023
Expression of FOXP3 in edited CD34+ cells
SEATTLE CHILDRENS HOSPITAL2 citations65
US12358970B2Jul 15, 2025
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
SEATTLE CHILDRENS HOSPITAL0 citations62
US12378546B2Aug 5, 2025
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US11959073B2Apr 16, 2024
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US11873479B2Jan 16, 2024
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US11008565B2May 18, 2021
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US10995332B2May 4, 2021
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US10947529B2Mar 16, 2021
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDRENS HOSPITAL0 citations60
US11712454B2Aug 1, 2023
Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogenous FOXP3 gene
SEATTLE CHILDRENS HOSPITAL0 citations58
US11400169B2Aug 2, 2022
Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid
SEATTLE CHILDRENS HOSPITAL0 citations58
US12595492B2Apr 7, 2026
Rapamycin resistant cells
SEATTLE CHILDRENS HOSPITAL0 citations56
US11987804B2May 21, 2024
Rapamycin resistant cells
SEATTLE CHILDRENS HOSPITAL1 citations56
US10494422B2Dec 3, 2019
CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
SEATTLE CHILDRENS HOSPITAL0 citations42
US11939594B2Mar 26, 2024
Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
SEATTLE CHILDRENS HOSPITAL0 citations40
SCHARENBERG ANDREW M
4 patentsUS8673557B2Mar 18, 2014
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SCHARENBERG ANDREW M21 citations87
US10407672B2Sep 10, 2019
Compositions and methods comprising the use of cell surface displayed homing endonucleases
SCHARENBERG ANDREW M3 citations71
US8614300B2Dec 24, 2013
Nucleic acids encoding a mut-T domain-containing polypeptide
SCHARENBERG ANDREW M0 citations50
US8153400B1Apr 10, 2012
Nucleic acids encoding a mutT domain-containing polypeptide
SCHARENBERG ANDREW M0 citations50
SEATTLE CHILDREN'S HOSPITAL
3 patentsUS10745690B2Aug 18, 2020
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDREN'S HOSPITAL1 citations70
US10745688B2Aug 18, 2020
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDREN'S HOSPITAL0 citations49
US10745689B2Aug 18, 2020
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
SEATTLE CHILDREN'S HOSPITAL0 citations49